The deal sees Britain’s AstraZeneca Plc led by Pascal Soriot sharing development and commercialization costs for the drug worldwide. For AstraZeneca the deal makes sense as it will replenish its pipeline as its cancer drug sales grow. In a significant… Read More ›
The drugmaker has begun the process of searching for Philip Hamptonwill’s successor. On Monday, drugmaker GlaxoSmithKline plc stated, Philip Hamptonwill, its chairman will be stepping down from his role. Hamptonwill has been GlaxoSmithKline’s chairman for more than three and a… Read More ›
Daniel O’Day is likely to joint Gilead Sciences sometime in 2019; a formal date has not been set. According to a source familiar with the matter at hand, Gilead Sciences Inc, a drugmaker, will appoint Roche Holding AG’s Daniel O’Day… Read More ›
Following the takeover Takada will join the ranks of the world’s top 10 drugmakers and will gain expertise in rare diseases, at the cost of a mountain-load of debt. On Wednesday, shareholders of Takeda Pharmaceutical approved the $59 billion takeover… Read More ›
He will be replaced by Michael Heuer, Roche’s regional head of Europe, the Middle East, Africa, and Latin America, until a permanent replacement is found. On Tuesday, Roche disclosed, Roland Diggelmann the head of its diagnostics division will be leaving… Read More ›
Sanofi’s strength in molecular oncology is likely to provide it a competitive edge over its peers as to what drives the growth of cancer tissues, how these cells functions and proliferation in the body. In a strategic development, French drugmaker,… Read More ›
The deal, one of the largest in the pharma industry, will place Takeda Pharma into the top ranks of global drugmakers. On Tuesday, in a strategic move Japan’s Takeda Pharma stated it has agreed to acquire London-listed Shire for $61.50… Read More ›
Amgen stated the U.S. repatriation tax will impact its current generally accepted accounting principles (GAAP) earnings forecast, but will not have any affect on its non-GAAP forecast. With U.S. President Donald Trump signing the new tax bill into law on… Read More ›
Ignyta’s precision drugs and diagnostic portfolio will help Roche increase its global footprint in the oncology department. On Friday, U.S. cancer drugmaker Ignyta Inc and Swiss drugmaker Roche disclosed that the Swiss pharmaceutical giant will acquire U.S. drugmaker for $1.7… Read More ›
Warning against excessive transparency, Novo Nordisk said the upcoming transparency bills could impact its growth potential in key markets. On Wednesday, drugmaker Novo Nordisk warned that the new legislation being prepared in some states in the U.S. which are aimed… Read More ›
manageria.biz 